Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAD Plus Low-Dose Thalidomide for Newly Diagnosed Multiple Myeloma
NCT00054158Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in multiple myeloma (MM), sponsored by Roswell Park Comprehensive Cancer Center. Started Aug 2004; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00054158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054158.